Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients.

Autor: Adamo A; Immunology section, Department of Medicine University and Hospital Trust of Verona, Verona, Italy., Frusteri C; Immunology section, Department of Medicine University and Hospital Trust of Verona, Verona, Italy., Pilotto S; Oncology section, Department of Engineering for Innovative Medicine and Hospital Trust of Verona, Verona, Italy., Caligola S; Veneto Institute of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IOV-IRCCS), Padova, Italy., Belluomini L; Oncology section, Department of Engineering for Innovative Medicine and Hospital Trust of Verona, Verona, Italy., Poffe O; Immunology section, Department of Medicine University and Hospital Trust of Verona, Verona, Italy., Giacobazzi L; Immunology section, Department of Medicine University and Hospital Trust of Verona, Verona, Italy., Dusi S; Veneto Institute of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IOV-IRCCS), Padova, Italy., Musiu C; Immunology section, Department of Medicine University and Hospital Trust of Verona, Verona, Italy., Hu Y; Immunology section, Department of Medicine University and Hospital Trust of Verona, Verona, Italy., Wang T; Immunology section, Department of Medicine University and Hospital Trust of Verona, Verona, Italy., Rizzini D; Immunology section, Department of Medicine University and Hospital Trust of Verona, Verona, Italy., Vella A; Immunology section, Department of Medicine University and Hospital Trust of Verona, Verona, Italy., Canè S; Veneto Institute of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IOV-IRCCS), Padova, Italy., Sartori G; Oncology section, Department of Engineering for Innovative Medicine and Hospital Trust of Verona, Verona, Italy., Insolda J; Oncology section, Department of Engineering for Innovative Medicine and Hospital Trust of Verona, Verona, Italy., Sposito M; Oncology section, Department of Engineering for Innovative Medicine and Hospital Trust of Verona, Verona, Italy., Incani UC; Oncology section, Department of Engineering for Innovative Medicine and Hospital Trust of Verona, Verona, Italy., Carbone C; Medical Oncology, Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy., Piro G; Medical Oncology, Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy., Pettinella F; General Pathology section, Department of Medicine University of Verona, Verona, Italy., Qi F; Department of Burns and Plastic Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, P.R. China., Wang D; Department of Burns and Plastic Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, P.R. China., Sartoris S; Immunology section, Department of Medicine University and Hospital Trust of Verona, Verona, Italy., De Sanctis F; Immunology section, Department of Medicine University and Hospital Trust of Verona, Verona, Italy., Scapini P; General Pathology section, Department of Medicine University of Verona, Verona, Italy., Dusi S; General Pathology section, Department of Medicine University of Verona, Verona, Italy., Cassatella MA; General Pathology section, Department of Medicine University of Verona, Verona, Italy., Bria E; Veneto Institute of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IOV-IRCCS), Padova, Italy., Milella M; Oncology section, Department of Engineering for Innovative Medicine and Hospital Trust of Verona, Verona, Italy., Bronte V; Veneto Institute of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IOV-IRCCS), Padova, Italy., Ugel S; Immunology section, Department of Medicine University and Hospital Trust of Verona, Verona, Italy.

Publikováno v: Oncoimmunology [Oncoimmunology] 2023 Sep 14; Vol. 12 (1), pp. 2253644. Date of Electronic Publication: 2023 Sep 14 (Print Publication: 2023).

Signaling intermediates (MAPK and PI3K) as therapeutic targets in NSCLC.

Autor: Ciuffreda L, Incani UC, Steelman LS, Abrams SL, Falcone I, Curatolo AD, Chappell WH, Franklin RA, Vari S, Cognetti F, McCubrey JA, Milella M; Division of Medical Oncology A, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy. michelemilella@hotmail.com.

Publikováno v: Current pharmaceutical design [Curr Pharm Des] 2014; Vol. 20 (24), pp. 3944-57.